Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Transgenic CYP2C19 mouse as a new animal model for hyperdopaminergism-induced hyperkinesia

Sep. 12, 2019

Tiziana presents phase I results for nasal foralumab

Sep. 12, 2019

Alector begins phase II study of AL-001 for frontotemporal dementia

Sep. 10, 2019

Phase II study of bryostatin-1 in moderate to severe Alzheimer's misses primary endpoint

Sep. 10, 2019

Cassava Sciences announces phase IIa data for PTI-125 in Alzheimer's disease

Sep. 10, 2019

Results from phase II ADAMANT trial of AADvac-1 in Alzheimer's disease reported

Sep. 10, 2019

Phospholipase D inhibitors developed for testing in neurodegeneration models

Sep. 10, 2019

Experimental model developed for PACAP-induced headache

Sep. 10, 2019

Cheerful gut bug has relationship with antidepressant

Sep. 10, 2019

Passage Bio licenses gene therapy program for CMT2A from Penn

Sep. 9, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 14, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...